参芪补肺方治疗慢阻肺稳定期（肺肾气虚兼血瘀证）的临床观察及对血清IL-17的影响

发布时间：2018-10-17 19:01

【摘要】：目的:观察参芪补肺方对慢阻肺稳定期(肺肾气虚兼血瘀证)患者的6min步行距离、症状积分、急性加重次数、血清IL-17水平的影响,评价其临床疗效及安全性。方法:共选取符合纳入标准的COPD稳定期患者64例,治疗组、对照组各32例,治疗组:给予噻托溴铵粉吸入剂每次1吸,每吸(18 μg),日1次,加服参芪补肺方,每日一剂,早晚饭后各服150ml,温水送服;对照组:给予噻托溴铵粉吸入剂每次1吸,每吸(18μg),日1次,加服补肺活血胶囊,每次4粒,每日3次口服。2组疗程均为90天。在治疗前后统计两组患者进行6min步行距离、血清IL-17水平、中医主证证候积分,统计两组治疗后6个月急性加重次数。结果:1.两组患者治疗后6min步行距离均上升(P0.05),但组间比较无差异(P0.05)。2.治疗后6个月治疗组急性加重次数明显少于对照组,组间比较有统计学意义(P0.05)。3.两组患者治疗后血清IL-17水平较治疗前均降低(P0.05);两组患者治疗后血清IL-17水平比较(P0.05),组间比较有统计学意义,治疗组降低血清IL-17水平优于对照组。4.两组患者治疗后中医主证证候总分均降低(P0.05),且治疗组优于对照组(P0.05)。5.两组患者中医主证证候疗效无统计学意义,疗效相当(P0.05)。6.两组患者治疗前后安全性指标检测均无临床意义。结论:1.参芪补肺方能改善患者中医主证证候、降低急性加重次数、提高6min步行距离。2.参芪补肺方能够降低血清中IL-17的水平。3.参芪补肺方安全有效,适宜在临床中推广应用。
[Abstract]:Objective: to observe the effect of Shenqi Bufei recipe on 6min walking distance, symptom score, acute exacerbation times and serum IL-17 level in patients with chronic obstructive lung at stable stage (lung and kidney qi deficiency and blood stasis syndrome), and to evaluate its clinical efficacy and safety. Methods: a total of 64 patients with stable COPD, 32 patients in treatment group and 32 patients in control group, were selected. The treatment group was given tiotropium bromide powder inhalation once a time (18 渭 g), / d), plus Shenqi Bufei recipe once a day. The control group was given tiotropium bromide powder inhaler once a time, every time (18 渭 g), day), plus Bufei Huoxue capsule, 4 capsules each time, 3 times a day. The course of treatment in both groups was 90 days. Before and after treatment, the walking distance of 6min, the level of serum IL-17, the integral of main syndromes of TCM and the times of acute exacerbation after 6 months of treatment were counted. The result is 1: 1. The walking distance of 6min increased in both groups after treatment (P0.05), but there was no difference between the two groups (P0.05). Six months after treatment, the number of acute exacerbations in the treatment group was significantly lower than that in the control group, and there was statistical significance between the two groups (P0.05). After treatment, the serum IL-17 level in the two groups was lower than that before treatment (P0.05), the serum IL-17 level in the two groups after treatment (P0.05), the comparison between the two groups was statistically significant, the treatment group decreased the serum IL-17 level was better than the control group. 4. After treatment, the total scores of main syndromes of TCM decreased in both groups (P0.05), and the treatment group was superior to the control group (P0.05). Two groups of patients with traditional Chinese medicine syndromes syndrome efficacy was not statistically significant, the efficacy was comparable (P0.05). 6. There was no clinical significance for the detection of safety indexes in both groups before and after treatment. Conclusion: 1. Shenqi Bufei prescription can improve the syndrome of TCM, reduce the times of acute aggravation, and improve the walking distance of 6min. 2. Shenqi Bufei prescription can reduce the level of IL-17 in serum. 3. 3. Shenqi Bufei prescription is safe and effective and suitable for clinical application.
【学位授予单位】：黑龙江中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R563.9

【相似文献】